Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G L Wampler

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Cancer Investigation|January 1, 1992
A pilot study of intensive weekly chemotherapy for extensive disease small-cell lung carcinomaG L Wampler, J D Ahlgren, R S Schulof
Cancer Research|May 1, 1978
Antitumor activity of amidoximes (hydroxyurea analogs) in murine tumor systemsK P Flora, B van't Riet, G L Wampler
Cancer Research|March 1, 1979
New ribonucleotide reductase inhibitors with antineoplastic activityH L Elford, G L Wampler, B van't Riet
Cancer Investigation|January 1, 1987
Combination of 5-fluorouracil and cyclophosphamide in L1210 and P388 leukemias with changes in optimum treatments as a function of the age of the L1210 tumor at first treatmentG L Wampler, W H Carter, E D Campbell
Cancer Treatment Reports|March 1, 1978
Combination chemotherapy: arriving at optimal treatment levels by incorporating side effect constraintsG L Wampler, W H Carter, V R Williams
Cancer Research|September 1, 1979
An improved method for analyzing survival data from combination chemotherapy experimentsW H Carter, D M Stablein, G L Wampler
Journal of Medicinal Chemistry|May 1, 1979
Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activityB van't Riet, G L Wampler, H L Elford
Biometrics|September 1, 1983
Confidence regions for constrained optima in response-surface experimentsD M Stablein, W H Carter, G L Wampler
Cancer Chemotherapy Reports|August 1, 1972
Hexamethylmelamine (NSC-13875) in the treatment of advanced cancerG L Wampler, S J Mellette, M Kuperminc, et al.
Journal of Medicinal Chemistry|February 1, 1975
Synthfsis of bis(aziridinyl)phosphinyl-N-hydroxyurethane derivatives as antineoplastic agentsY Y Hsiao, T J Bardos, G L Wampler, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Cancer Investigation|January 1, 1992
A pilot study of intensive weekly chemotherapy for extensive disease small-cell lung carcinomaG L Wampler, J D Ahlgren, R S Schulof
Cancer Research|May 1, 1978
Antitumor activity of amidoximes (hydroxyurea analogs) in murine tumor systemsK P Flora, B van't Riet, G L Wampler
Cancer Research|March 1, 1979
New ribonucleotide reductase inhibitors with antineoplastic activityH L Elford, G L Wampler, B van't Riet
Cancer Investigation|January 1, 1987
Combination of 5-fluorouracil and cyclophosphamide in L1210 and P388 leukemias with changes in optimum treatments as a function of the age of the L1210 tumor at first treatmentG L Wampler, W H Carter, E D Campbell
Cancer Treatment Reports|March 1, 1978
Combination chemotherapy: arriving at optimal treatment levels by incorporating side effect constraintsG L Wampler, W H Carter, V R Williams
Cancer Research|September 1, 1979
An improved method for analyzing survival data from combination chemotherapy experimentsW H Carter, D M Stablein, G L Wampler
Journal of Medicinal Chemistry|May 1, 1979
Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activityB van't Riet, G L Wampler, H L Elford
Biometrics|September 1, 1983
Confidence regions for constrained optima in response-surface experimentsD M Stablein, W H Carter, G L Wampler
Cancer Chemotherapy Reports|August 1, 1972
Hexamethylmelamine (NSC-13875) in the treatment of advanced cancerG L Wampler, S J Mellette, M Kuperminc, et al.
Journal of Medicinal Chemistry|February 1, 1975
Synthfsis of bis(aziridinyl)phosphinyl-N-hydroxyurethane derivatives as antineoplastic agentsY Y Hsiao, T J Bardos, G L Wampler, et al.
Pageof 6